(Q45530158)

English

Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients

scientific article published in October 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

immunohistochemistry

1 reference

based on heuristic

inferred from title

Tryfonia Mainou-Fowler

8

object named as

Tryfonia Mainou-Fowler

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Rachel E Culpin

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Michal Sieniawski

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Brian Angus

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Geetha K Menon

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Stephen J Proctor

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Paul Milne

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Kate McCabe

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

publication date

1 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

788-801

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Building an outcome predictor model for diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Con

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Evaluation of intra- and interobserver agreement and its clinical significance for scoring bcl-2 immunohistochemical expression in diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

1 reference

https://api.crossref.org/works/10.1111%2FHIS.12223

21 January 2018

Identifiers

10.1111/HIS.12223

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45530158&oldid=2176126753"